Press release
Emerging Age-related Macular Degeneration (AMD) Therapies: Key Pipeline Drugs and Companies Advancing AMD Treatment | DelveInsight
Key takeaways from the AMD Clinical Trial Landscape Report
• DelveInsight's AMD pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Age-related Macular Degeneration treatment.
• Key AMD companies such as Stealth BioTherapeutics, Merck, 4D Molecular Therapeutics, Evergreen Therapeutics, HuidaGene Therapeutics, Sanofi, and others
• Promising AMD pipeline therapies in various stages of development include Elamipretide, MK-8748, 4D-150, EG-301, HG202, SAR402663, and others.
Request a sample and discover the recent advances in AMD treatment drugs
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Age-related Macular Degeneration (AMD)?
Age-related Macular Degeneration is a progressive macular disorder and a leading cause of central vision loss in older adults. It affects the outer retina, including photoreceptors and retinal pigment epithelium dysfunction, leading to gradual degeneration of central vision. AMD progresses from early to late stages and is broadly classified into dry AMD and wet AMD. Dry AMD develops gradually with drusen accumulation and macular thinning, whereas wet AMD is characterized by abnormal blood vessel growth and rapid vision deterioration. Symptoms include blurred vision, distortion of straight lines, reduced color perception, and difficulty recognizing faces. Diagnosis involves retinal imaging techniques such as OCT, fundus photography, and visual acuity assessments. Current treatment approaches include anti-VEGF therapies for wet AMD and complement inhibitors, lifestyle measures, and investigational therapies for dry AMD.
Emerging AMD Drug Profiles
Elamipretide: Stealth BioTherapeutics
Elamipretide is a mitochondria-targeting peptide designed to improve cellular energy production and reduce oxidative stress, key drivers in Age-related Macular Degeneration. The therapy works by stabilizing cardiolipin in the mitochondrial membrane, helping preserve retinal pigment epithelium and photoreceptor function. Elamipretide is currently being evaluated in a Phase III clinical trial for the treatment of dry AMD.
MK-8748: Merck
MK-8748 is an investigational bispecific antibody being developed by Merck for the treatment of neovascular (wet) AMD. The therapy directly activates Tie2 signaling while inhibiting vascular endothelial growth factor (VEGF), aiming to improve vascular stability and reduce retinal leakage associated with disease progression.
Learn more about the novel and emerging AMD pipeline therapies
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Recent Developments in the AMD Clinical Trial Landscape
• In April 2026, Merck announced the initiation of a pivotal Phase IIb/III trial evaluating MK-8748 for the treatment of neovascular Age-related Macular Degeneration.
• In February 2026, 4D Molecular Therapeutics announced completion of enrollment for the Phase III 4FRONT-1 trial evaluating 4D-150 in patients with wet AMD.
• In September 2025, the US Food and Drug Administration granted Fast Track designation to SAR402663, an investigational intravitreal gene therapy for the treatment of neovascular AMD.
• In January 2026, Stealth BioTherapeutics announced that the fully enrolled Phase III ReNEW trial evaluating Elamipretide for dry AMD is expected to read out in late 2027.
• In October 2025, Eli Lilly and Company announced the acquisition of Adverum Biotechnologies, including its lead intravitreal gene therapy candidate Ixo-vec for wet AMD.
Scope of the AMD Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Preclinical, Phase I, Phase II, Phase II/III, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravitreal, Subcutaneous, Subretinal
• Therapeutics Assessment By Molecule Type: Peptide, Gene therapy, Bispecific antibody, Small molecule, Protein replacement therapies
• Key AMD Companies: Stealth BioTherapeutics, Merck, 4D Molecular Therapeutics, Evergreen Therapeutics, HuidaGene Therapeutics, Sanofi, and others
• Key AMD Pipeline Therapies: Elamipretide, MK-8748, 4D-150, EG-301, HG202, SAR402663, and others
Dive deep into rich insights for new drugs for AMD treatment, visit
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. AMD Pipeline Report Introduction
2. AMD Pipeline Report Executive Summary
3. AMD Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. AMD Pipeline Therapeutics
6. AMD Pipeline: Late Stage Products (Phase III)
7. AMD Pipeline: Mid Stage Products (Phase II/III)
8. AMD Pipeline: Mid Stage Products (Phase II)
9. AMD Pipeline: Early Stage Products (Phase I)
10. AMD Pipeline Therapeutics Assessment
11. Inactive Products in the AMD Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the AMD Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the AMD pipeline therapeutics, reach out
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Age-related Macular Degeneration (AMD) Therapies: Key Pipeline Drugs and Companies Advancing AMD Treatment | DelveInsight here
News-ID: 4513875 • Views: …
More Releases from DelveIinsight Business Research
Rheumatoid Arthritis Market is Projected to Grow Significantly by 2036 Owing to …
The market dynamics for Rheumatoid Arthritis are witnessing steady growth driven by the increasing prevalence of autoimmune disorders, rising geriatric population, growing demand for targeted biologics and oral therapies, and continuous advancements in immunomodulatory treatments. Additionally, the launch of emerging therapies such as LNK01001 (Lynk Pharmaceuticals), AP1189/Resomelagon (SynAct Pharma), Ocadusertib (Eli Lilly and Company), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of…
Febrile Neutropenia Market is Projected to Grow Significantly by 2036 Owing to t …
The market dynamics for Febrile Neutropenia are witnessing steady growth driven by the increasing incidence of cancer, rising use of myelosuppressive chemotherapy, growing demand for effective supportive care therapies, and expanding adoption of granulocyte-colony stimulating factors (G-CSFs). Additionally, the launch of emerging therapies such as Plinabulin (BeyondSpring), AKT-011 (Akthelia Pharmaceuticals), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's…
Acute Kidney Injury (AKI) Clinical Trial Pipeline Analysis: 20+ Key Companies Sh …
DelveInsight's Acute Kidney Injury (AKI) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Acute Kidney Injury therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Kidney Injury pipeline domain.
Key takeaways from the Acute Kidney Injury Clinical Trial Landscape Report
• DelveInsight's Acute Kidney Injury pipeline report depicts a robust space with 20+…
Migraine Market is Projected to Grow Significantly by 2036 Owing to the Rising D …
The market dynamics for Migraine are witnessing steady growth driven by the rising prevalence of chronic and episodic migraine, increasing awareness and diagnosis rates, expanding adoption of preventive therapies, and growing demand for CGRP-targeted treatment options. Additionally, the launch of emerging therapies such as Elismetrep (K-304) by Kallyope, Lu AG09222 by Lundbeck, and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest…
More Releases for AMD
Onlive Server Brings AI-Powered AMD Dedicated Servers
We are all aware of how useful, and sometimes even crucial, proper hosting services can be for a business. That is why Onlive Server is providing this new option with the newly recommended AI-powered AMD Dedicated Server Hosting[https://onliveserver.com/amd-dedicated-server-hosting/]. Furthermore, these servers are powered by AMD technology and do superbly in servicing the tremendous demand of agile business workloads with modern AI computations, big data, and other emerging technologies.
AI-powered solutions are…
Age-related Macular Degeneration AMD Drugs Market Demand Driven by Rising Preval …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Report By Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User (Hospitals, Specialty Centers, Long-Term Care Facilities)- Market Outlook And Industry Analysis 2031"
The…
Age-Related Macular Degeneration Market To Expand, Fuelled By Innovations In Dry …
The Age-related Macular Degeneration Market (AMD) is poised for significant growth over the coming years, with projections indicating a compound annual growth rate (CAGR) of 6.2%, leading to an estimated market value of $20 billion by the end of the forecast period. This robust expansion is driven by several critical factors, including the rising prevalence of eye diseases, advancements in medical technology, and an aging population that is increasingly susceptible…
AMD Workstations Market | BIZON, BOXX Technologies, Broadberry, Dell
The global amd workstations market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the amd workstations market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Airway Management Products (AMD) Market 2021 | Detailed Report
Airway Management Products (AMD) Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5262437
The report provides a comprehensive analysis of company profiles listed below:
- Medtronic
- Teleflex
- Ambu
- Smiths Medical
- Intersurgical
- Becton Dickinson
- Armstrong Medical
- Medline Industries
Airway Management Products…
Age-Related Macular Degeneration (AMD) Market Report 2018: Segmentation by Type …
Global Age-Related Macular Degeneration (AMD) market research report provides company profile for F. Hoffmann-La Roche AG, Regeneron Pharmaceutical Inc., Novartis AG, Bayer AG, Santen Pharmaceuticals and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc.…
